biote (BTMD) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• biote will report Q1 2026 results after the market on Wednesday, May 6, 2026 at 5:00 PM ET, with analysts expecting $0.09 EPS and $46.022 million in revenue.
• The stock opened around $2.25 (market cap ≈ $88.99M, PE ~3.0) and carries an average analyst rating of "Hold" with an average target of $2.75 after several recent price cuts and mixed buy/hold/sell opinions.
• biote operates a niche practice-building platform in the hormone optimization space, offering training, certification, practice-management software, inventory tools, and marketing support for practitioners using bioidentical hormone pellet therapy.

biote (NASDAQ:BTMD - Get Free Report) is expected to be announcing its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $46.0220 million for the quarter. Investors are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 5:00 PM ET.

biote (NASDAQ:BTMD - Get Free Report) last released its earnings results on Wednesday, March 11th. The company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $0.01. biote had a net margin of 14.07% and a negative return on equity of 23.41%. The business had revenue of $46.41 million during the quarter, compared to analysts' expectations of $45.79 million. On average, analysts expect biote to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

biote Trading Down 0.9%

Shares of NASDAQ BTMD opened at $2.25 on Wednesday. biote has a 12-month low of $1.27 and a 12-month high of $4.75. The stock has a market cap of $88.99 million, a PE ratio of 3.00 and a beta of 1.29. The company has a 50-day moving average of $1.80 and a 200 day moving average of $2.29.

Analysts Set New Price Targets

Several analysts recently issued reports on BTMD shares. National Bank Financial set a $2.50 price objective on shares of biote in a research note on Thursday, March 12th. Truist Financial dropped their price objective on shares of biote from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, April 16th. TD Cowen dropped their price objective on shares of biote from $3.00 to $2.50 and set a "buy" rating for the company in a research note on Thursday, March 12th. Finally, B. Riley Financial dropped their price target on shares of biote from $3.00 to $2.00 and set a "neutral" rating for the company in a research note on Thursday, March 12th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, biote currently has an average rating of "Hold" and an average target price of $2.75.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of BTMD. Cubist Systematic Strategies LLC purchased a new position in shares of biote in the 1st quarter valued at $76,000. AQR Capital Management LLC purchased a new position in shares of biote in the 1st quarter valued at $43,000. Geode Capital Management LLC grew its position in shares of biote by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 616,697 shares of the company's stock valued at $2,480,000 after buying an additional 41,333 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of biote in the 2nd quarter valued at $68,000. Finally, First Trust Advisors LP grew its position in shares of biote by 5.3% in the 2nd quarter. First Trust Advisors LP now owns 73,669 shares of the company's stock valued at $296,000 after buying an additional 3,675 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.